(Q37835571)

24 August 2017

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. (English)

1 reference

24 August 2017

0 references

Hervé Avet-Loiseau

0 references

Athanasios Dimopoulos

Meletios Dimopoulos

0 references

Jesus San Miguel

0 references

Robert Kyle

1 reference

24 August 2017

Sagar Lonial

1 reference

24 August 2017

Kenneth C Anderson

1 reference

24 August 2017

Paul Richardson

1 reference

24 August 2017

S Vincent Rajkumar

1 reference

24 August 2017

Antonio Palumbo

1 reference

24 August 2017

Thierry Facon

1 reference

24 August 2017

Heinz Ludwig

1 reference

24 August 2017

Robert Orlowski

1 reference

24 August 2017

Nikhil C Munshi

1 reference

24 August 2017

Sundar Jagannath

1 reference

24 August 2017

Orhan Sezer

1 reference

24 August 2017

Joan Blade

1 reference

24 August 2017

David Vesole

1 reference

24 August 2017

Jean-Luc Harousseau

1 reference

International Myeloma Workshop Consensus Panel 1

24 August 2017

series ordinal

object named as

International Myeloma Workshop Consensus Panel 1

1 reference

24 August 2017

Jeffrey Zonder

1 reference

24 August 2017

Brian Durie

1 reference

24 August 2017

David Siegel

1 reference

24 August 2017

language of work or name

English

0 references

publication date

3 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

117

1 reference

24 August 2017

1 reference

24 August 2017

4691-4695

1 reference

The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma

24 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710442

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710442

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710442

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710442

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710442

International uniform response criteria for multiple myeloma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710442

A phase 2 study of bortezomib in relapsed, refractory myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710442

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710442

The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710442

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710442

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 September 2018

1 reference

12 December 2020

Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide

1 reference

12 December 2020

Clinically relevant end points and new drug approvals for myeloma

1 reference

12 December 2020

Eliminating the complete response penalty from myeloma response assessment

1 reference

12 December 2020

Eliminating the complete response penalty from myeloma response criteria

1 reference

12 December 2020

10.1182/BLOOD-2010-10-299487

Identifiers

DOI

1 reference

24 August 2017

1 reference

24 August 2017

PubMed publication ID

21292775

1 reference